ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Roupret M, Bertaut A, Pignot G, Neuzillet Y, Houede N, Mathieu R, Corbel L, Besson D, Seisen T, Jaffrelot L, Lebacle C, Champiat S, Lebdai S, Timsit MO, Thibault C, Goeman L, Juárez Soto Á, La C, Léger C, Loriot Y

Open source

DOI: 10.1016/j.annonc.2025.09.017
Published: 2026 Jan
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2025.09.017,
  title = {ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).},
  author = {Roupret M and Bertaut A and Pignot G and Neuzillet Y and Houede N and Mathieu R and Corbel L and Besson D and Seisen T and Jaffrelot L and Lebacle C and Champiat S and Lebdai S and Timsit MO and Thibault C and Goeman L and Juárez Soto Á and La C and Léger C and Loriot Y},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2025.09.017},
  url = {https://doi.org/10.1016/j.annonc.2025.09.017}
}

RIS

TY  - JOUR
TI  - ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).
AU  - Roupret M
AU  - Bertaut A
AU  - Pignot G
AU  - Neuzillet Y
AU  - Houede N
AU  - Mathieu R
AU  - Corbel L
AU  - Besson D
AU  - Seisen T
AU  - Jaffrelot L
AU  - Lebacle C
AU  - Champiat S
AU  - Lebdai S
AU  - Timsit MO
AU  - Thibault C
AU  - Goeman L
AU  - Juárez Soto Á
AU  - La C
AU  - Léger C
AU  - Loriot Y
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2025.09.017
UR  - https://doi.org/10.1016/j.annonc.2025.09.017
ER  -

APA

M, R., A, B., G, P., Y, N., N, H., R, M., L, C., D, B., T, S., L, J., C, L., S, C., S, L., MO, T., C, T., L, G., Á, J. S., C, L., C, L., & Y, L. (2026). ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2025.09.017

Source records

pubmed · retrieved 2026-09-26T09:41:36.788Z